Several analysts have recently updated their ratings and price targets for Allergan PLC. (NYSE: AGN):

  • 8/9/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $280.00 price target on the stock, up previously from $270.00.
  • 8/9/2017 – Allergan PLC. was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/9/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $278.00 price target on the stock, up previously from $273.00.
  • 8/9/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at UBS Group AG. They now have a $275.00 price target on the stock.
  • 8/5/2017 – Allergan PLC. was given a new $288.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.
  • 8/3/2017 – Allergan PLC. had its price target raised by analysts at Wells Fargo & Company to $278.00. They now have an “outperform” rating on the stock.
  • 8/3/2017 – Allergan PLC. was given a new $285.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 8/2/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $267.00 price target on the stock.
  • 7/20/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $286.00 price target on the stock, up previously from $274.00.
  • 7/17/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $273.00 price target on the stock, up previously from $265.00.
  • 7/16/2017 – Allergan PLC. was given a new $284.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 7/14/2017 – Allergan PLC. had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $231.00 price target on the stock.
  • 7/11/2017 – Allergan PLC. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $270.00 price target on the stock. According to Zacks, “Allergan is reshaping its portfolio through strategic acquisitions. Following the closure of the Teva deal, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Key products like Botox and Linzess and new products are supporting sales growth. Allergan’s share price has outperformed the broader industry, so far this year. It also boasts a strong pipeline. Biosimilars also represent significant opportunity. While we remain optimistic about the company’s growth prospects, it is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also new competition for key growth drivers, Restasis and Linzess, is an investor concern. Estimates have gone up ahead of the Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters.”
  • 6/26/2017 – Allergan PLC. was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $242.88 price target on the stock.
  • 6/24/2017 – Allergan PLC. was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/19/2017 – Allergan PLC. was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $234.38 price target on the stock.
  • 6/17/2017 – Allergan PLC. was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/16/2017 – Allergan PLC. is now covered by analysts at Cantor Fitzgerald. They set a “neutral” rating and a $231.00 price target on the stock.
  • 6/12/2017 – Allergan PLC. was given a new $284.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.

Allergan PLC. (NYSE:AGN) opened at 232.20 on Friday. The company has a market cap of $77.83 billion, a P/E ratio of 7.07 and a beta of 1.16. The stock’s 50 day moving average price is $246.34 and its 200 day moving average price is $238.00. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter last year, the firm earned $3.35 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. Analysts expect that Allergan PLC. will post $16.25 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.21%. Allergan PLC.’s dividend payout ratio is presently 9.95%.

In related news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.36% of the stock is currently owned by company insiders.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.